40. Lenzilumab Efficacy and Safety in Newly Hospitalized COVID-19 Subjects: Results From a Phase 3 Randomized Double-Blind Placebo-Controlled Trial

BACKGROUND: Severe coronavirus disease 2019 (COVID-19) often results from the immune-mediated cytokine storm, triggered by granulocyte macrophage-colony stimulating factor (GM-CSF), potentially leading to respiratory failure and death. Lenzilumab, a novel anti-human GM-CSF monoclonal antibody, neutr...

Descripción completa

Detalles Bibliográficos
Autores principales: Temesgem, Zelalem, Burger, Charles, Baker, Jason, Polk, Christopher, Libertin, Claudia R, Kelley, Colleen F, Marconi, Vincent, Orenstein, Robert, Catterson, Victoria, Aronstein, William, Durrant, Cameron, Chappell, Dale, Ahmed, Omar, Chappell, Gabrielle, Badley, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Oral Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643764/
http://dx.doi.org/10.1093/ofid/ofab466.040

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643764/
http://dx.doi.org/10.1093/ofid/ofab466.040

Ejemplares similares